KH.S. KHAERTYNOV¹, V.A. ANOKHIN¹, O.V. ZHEMKOVA², L.KH. VALIAKHMETOVA², N.A. SHAYKHUTDINOVA², L.YU. MALYKHINA², T.S. UTYUSHEVA², A.E. EVDOKIMOVA¹, E.I. NASYROVA¹

 ¹Kazan State Medical University, Kazan

²Republic Clinical Infectious Diseases Hospital named after Prof. A.F. Agafonov, Kazan

 Contact details:

Khaertynov Kh.S. — MD, Associate Professor of the Department of Children’s Infections

Address: 49 Butlerov St., Kazan, Russian Federation, 420110, tel.: +7-903-342-96-27, e-mail: khalit65@yandex.ru

Endothelial dysfunction is the main cause of thrombotic complications and unfavorable disease outcome in COVID-19. The study of markers of endothelial dysfunction in patients with COVID-19 will help to determine additional directions for the treatment of hemostatic disorders.

The purpose — to evaluate the diagnostic significance of endothelial dysfunction markers in moderate and severe forms of COVID-19.

Material and methods. The study was carried out in 28 patients with COVID-19 hospitalized at the Republic Clinical Infectious Diseases Hospital (Kazan) from 02.16.2023 to 03.07.2023. The median age of patients was 66.5 years. The control group consisted of 20 healthy people of the same age.

Results. It was found that moderate and severe forms of COVID-19 are accompanied by increased values of D-dimer and VWF in the blood, the medians of which were 2.6 and 1.9 times higher than control values, respectively. No significant differences in the values of P-selectin and thrombomodulin were detected in the compared groups. A moderate correlation was established between the level of P-selectin and the absolute number of neutrophils in the blood. It was found that the values of D-dimer and thrombomodulin were significantly higher in patients with COVID-19 who had two or more comorbid diseases. The high likelihood ratios of FFB and D-dimer positivity (LR+ = 8.4) allow considering them as reliable parameters for assessing endothelial dysfunction in patients with COVID-19.

Conclusion. Endothelial dysfunction in COVID-19 disease is manifested by increased levels of D-dimer and VWF in the blood. The identified changes indicate the possibility of using medications that neutralize VWF in addition to anticoagulant drugs.

Key words: coronavirus infection COVID-19, endothelial dysfunction.

REFERENCES

1. Iba T., Warkentin T.E, Thachil J. et al. Proposal of the Definition for COVID-19-Associated Coagulopathy. J. Clin. Med, 2021, vol. 10 (2), p. 191. DOI: 10.3390/jcm10020191
2. Makatsariya A.D., Slukhanchuk E.V., Bitsadze V.O. et al. COVID-19, hemostasis disorders and the risk of thrombotic complications. Vestnik RAMN, 2020, vol. 57, no. 4, pp. 306–317 (in Russ.).
3. Chen W., Pan J.Y. Anatomical and pathological observation and analysis of SARS and COVID-19: microthrombosis is the main cause of death. Biol. Proc. Online, 2021, vol. 23, pp. 1–12. DOI: 10.1186/s12575-021-00142-y
4. Khismatullin R.R., Ivaeva R.A., Abdullaeva Sh. et al. Pathomorphological manifestations of inflammatory microthrombosis in COVID-19. Kazanskiy meditsinskiy zhurnal, 2022, vol. 103, no. 4, pp. 575–587 (in Russ.).
5. Fodor A., Tiperciuc B., Login C. et al. Endothelial dysfunction, inflammation, and oxidative stress in COVID-19 — mechanisms and therapeutic targets. OMCL, 2021. Article ID 8671713.
6. Ladikou E.E., Sivaloganathan H., Milne K.M. et al. Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19? Clin. Med. (Lond), 2020, vol. 20 (5), pp. e178–182. DOI: 10.7861/clinmed.2020-0346
7. Andrianto A., Rizkiawan R., Harsoyo P.M. et al. COVID-19 and endothelial dysfunction: biomarkers and potential drug mechanismsct. Indonesian J. Trop. Infect. Dis, 2021, vol. 9 (2), pp. 108–119. DOI: 10.20473/ijtid.v9i2.25489
8. Watanabe-Kusunoki K., Nakazawa D., Ishizu A. et al. Thrombomodulin as a physiological modulator of intravascular injury. Front. Immunol, 2020, vol. 11, 575890. DOI: 10.3389/fimmu.2020.575890
9. Pons S., Fodil S., Azoulay E. et al. The vascular endothelium: The cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit. Care, 2020, vol. 24, p. 353. DOI: 10.1186/s13054-020-03062-7
10. Tvaroška I., Selvaraj C., Koˇca J. Selectins-the two Dr. Jekyll and Mr. Hyde faces of adhesion molecules — a review. Molecules, 2020, vol. 19, p. 2835.
11. Watany M.M., Abdou S., Elkolaly R. et al. Evaluation of admission levels of P, E and L selectins as predictors for thrombosis in hospitalized COVID 19 patients. Clin. Exp. Med, 2022, vol. 22, pp. 567–575. DOI: 10.1007/s10238-021-00787-9
12. Goshua G., Pine A.B., Meizlish M.L. et al. Endotheliopathy in COVID-19-associated coagulopathy: Evidence from a single-centre, cross-sectional study. Lancet Haematol, 2020, vol. 7 (8), pp. 575–582. doi: 10.1016/S2352-3026(20)30216-7.
13. Fenyves B.G., Mehta A., Kays K.R. et al. Plasma P-selectin is an early marker of thromboembolism in COVID-19. Am. J. Hematol, 2021, vol. 96 (12), pp. E468–471. DOI: 10.1002/ajh.26372
14. Agrati C., Sacchi A., Tartaglia E. et al. The role of P-Selectin in COVID-19 coagulopathy: an updated review. Int. J. Mol. Sci, 2021, vol. 22 (15), pp. 7942. DOI: 10.3390/ijms22157942
15. Middleton E.A., He X.-Y., Denorme F. et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood, 2020, vol. 136 (10), pp. 1169–1179. DOI: 10.1182/blood.2020007008
16. Wang Z.F., Su F., Lin X.J. et al. Serum D-dimer changes and prognostic implication in 2009 novel influenza A(H1N1). Thromb. Res, 2011, vol. 127 (3), pp. 198–201. DOI: 10.1016/j.thromres.2010.11.032
17. Klok F.A., Kruip M., van der Meer N.J.M. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res, 2020, vol. 191, pp. 145–147. DOI: 10.1016/j.thromres.2020.04.013
18. Li Y., Deng Y., Ye L. et al. Clinical significance of plasma D-dimer in COVID-19 mortality. Front. Med, 2021, vol. 8, 638097. DOI: 10.3389/fmed.2021.638097
19. Lobastov K.V., Schastlivtsev I.V., Porembskaya O.Ya. et al. COVID-19-associated coagulopathy: review of modern recommendations for diagnosis, treatment and prevention. Ambulatornaya khirurgiya, 2020, no. 3–4, pp. 36–51 (in Russ.). DOI: 10.21518/1995-1477-2020-3-4-36-51
20. Tang N., Li D., Wang X. et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost, 2020, vol. 18 (4), pp. 844–847. DOI: 10.1111/jth.14768
21. Khaertynov Kh.S., Anokhin V.A. Khaliullina S.V et al. Inflammation and hemostasis in patients with severe form of coronavirus infection COVID-19. Meditsinskiy vestnik Bashkortostana, 2023, vol. 18, no. 4, pp. 11–17 (in Russ.).
22. Sayyadi M., Hassani S., Shams M. et al. Status of major hemostatic components in the setting of COVID 19: the effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement. Ann. Hematol, 2023, vol. 102 (6), pp. 1307–1322. DOI: 10.1007/s00277-023-05234-1
23. Zheng X.L. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu. Rev. Med, 2015, vol. 66, pp. 211–225. DOI: 10.1146/annurev-med-061813-013241
24. Fujikawa K., Suzuki H., McMullen B. et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood, 2001, vol. 98 (6), pp. 1662–1666. DOI: 10.1182/blood.V98.6.1662.
25. Hafez W., Ziade M.A., Arya A. et al. Reduced ADAMTS13 activity in correlation with pathophysiology, severity, and outcome of COVID-19: a retrospective observational study. Int. J. Infect. Dis, 2022, vol. 117, pp. 334–344. DOI: 10.1016/j.ijid.2022.02.019
26. Doevelaar A.A.N., Bachmann M., Hölzer B. et al. Von Willebrand factor multimer formation contributes to immunothrombosis in coronavirus disease 2019. Crit. Care Med, 2021, vol. 49 (5), pp. E512–520. DOI: 10.1097/CCM.0000000000004918
27. Akin’shina S.V., Bitsadze V.O., Andreeva M.D., Makatsariya A.D. Thrombotic microangiopathy. Prakticheskaya meditsina, 2013, vol. 76, no. 7, pp. 7–19 (in Russ.).
28. Wibowo A., Pranata R., Lim M.A. et al. Endotheliopathy marked by high von Willebrand factor (vWF) antigen in COVID-19 is associated with poor outcome: a systematic review and meta-analysis. Int. J. Infect. Dis, 2022, vol. 117, pp. 267–273. DOI: 10.1016/j.ijid.2021.06.051
29. Watanabe-Kusunoki K., Nakazawa D., Ishizu A. and Atsumi T. Thrombomodulin as a Physiological Modulator of Intravascular Injury. Front. Immunol, 2020, vol. 11, 575890. DOI: 10.3389/fimmu.2020.575890
30. Francischettia I.M.B., Toomera K., Zhang Y. et al. Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection. EClinical Medicine, 2021, vol. 39, 101069. DOI: 10.1016/j.eclinm.2021.101069.
31. Yamaoka-Tojo M. Vascular endothelial glycocalyx damage in COVID-19. Int. J. Mol. Sci, 2020, vol. 21 (24), p. 9712. DOI: 10.3390/ijms21249712
32. Helms J., Tacquard C., Severac F. et al. igh risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study. Int. Care Med, 2020, vol. 46, pp. 1089–1098. DOI: 10.1007/s00134-020-06062-x
33. Gragnano F., Sperlongano S., Golia E. et al. The role of von Willebrand factor in vascular inflammation: from pathogenesis to targeted therapy. Hindawi Mediators of Inflammation, vol. 2017. Article ID 5620314.